USRE36744E - Nasal administration of benzodiazepine hypnotics - Google Patents

Nasal administration of benzodiazepine hypnotics Download PDF

Info

Publication number
USRE36744E
USRE36744E US08/213,498 US21349894A USRE36744E US RE36744 E USRE36744 E US RE36744E US 21349894 A US21349894 A US 21349894A US RE36744 E USRE36744 E US RE36744E
Authority
US
United States
Prior art keywords
composition
benzodiazepine
iaddend
iadd
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/213,498
Inventor
Arthur H. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt ARD Inc
Original Assignee
Ribogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/245,031 external-priority patent/US4950664A/en
Application filed by Ribogene Inc filed Critical Ribogene Inc
Priority to US08/213,498 priority Critical patent/USRE36744E/en
Application granted granted Critical
Publication of USRE36744E publication Critical patent/USRE36744E/en
Assigned to RIBOGENE, INC. reassignment RIBOGENE, INC. REMOVAL OF SECURITY INTEREST Assignors: ASHKIN, MICHAEL, HYLINE LABORATORIES, INC.
Assigned to QUESTCOR PHARMACEUTICALS, INC. reassignment QUESTCOR PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RIBOGENE, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Definitions

  • the present invention relates to a novel form of certain hypnotic drugs and to their administration to mammals. They may be employed for any of the conventional purposes for which hypnotics are known, but especially for improving sleep.
  • Hypnotic drugs are a class of therapeutic agents which are commonly employed to induce and/or to prolong sleep. They may also be utilized to alleviate sleep disorders. Terms such as sedative, anti-anxiety agent, minor tranquilizer and anxiolytic are sometimes used somewhat interchangeably for such drugs because, in appropriate dosages, these hypnotics can produce similar effects.
  • hypnotic drugs There are a wide variety of hypnotic drugs. This term includes both barbiturates and non-barbiturates. Typical barbiturate hypnotics are aprobarbital and pentobarbital. Non-barbiturates recognized for their hypnotic activity include benzodiazepines; antihistamines having pronounced side effects such as diphenhydramine; serotonin initiators such as L-tryptophane; and various other drugs including ethinamate, chloral hydrate, ethchlorvynol, methyprylon and glutethimide. Their hypnotic effect is commonly attributed to a neurological mechanism involving depression of the central nervous system. That effect is also frequently accompanied by a mild reduction in such physiological functions as blood pressure and respiration.
  • nasal delivery of therapeutic agents is a relatively recently discovered technique. It is also recognized only for specific agents.
  • Representative disclosures of nasal administration of drugs include: U.S. Pat. No. 4,454,140 of Goldberg et al; U.S. Pat. No's. 4,428,883; 4,284,648; and 4,394,390 of Hussain and U.S. Pat. No. 4,624,965 of Wenig.
  • nasal administration has become an accepted route of administration, the foregoing disclosures limit that mode of delivery to the specific drugs described. Moreover, it has been observed that many therapeutic agents cannot be usefully administered by this unusual route. Consequently, nasal administration remains a technique for which applicability is far from universal and the results unpredictable.
  • compositions which contain a benzodiazepine hypnotic adapted for nasal administration and comprise a solution, suspension, ointment, gel or other useful nasal form.
  • nasal compositions may be employed for any of the known therapeutic purposes for which such hypnotics are known.
  • nasal administration greatly facilitates administration. As compared with parenteral administration, for example, a simple aerosol container or a dropper will suffice for delivery. From a therapeutic standpoint, nasal administration often provides a hypnotic effect of improved duration. It may also be more efficiently and precisely controlled than through conventional means and permits a more rapid onset of activity.
  • FIG. 1 is a graphic depiction of the comparative results of Example 1;
  • FIG. 2 is a graphic depiction of the comparative results of Example 2.
  • FIG. 3 is a graphic depiction of the comparative results of Example 3.
  • Any benzodiazepine drug capable of exhibiting a hypnotic activity may be employed in accordance with the present invention. These particularly include diazepam, triazolam, midazolam, temazepam and flurazepam; although other, less common benzodiazepines may also be utilized.
  • any pharmaceutically acceptable form of these benzodiazepine drugs may be utilized in accordance with the present invention.
  • the selected therapeutic agent is provided in the chemical form which has previously been found most efficacious for oral or parenteral delivery. Most commonly, this comprises either the free base or a pharmaceutically acceptable salt of the hypnotic agent.
  • a peculiar facet of the present invention lies in the discovery of the uniqueness of this class of hypnotics. Despite the recognized equivalence of benzodiazepines with other subclasses of hypnotics, they do not provide the many advantages enjoyed through the nasal administration of benzodiazepines. In fact, it has been discovered that many of these non-benzodiazepine hypnotics fail to exhibit that therapeutic activity when they are administered nasally, instead of by conventional method.
  • compositions containing the therapeutic drug in a form having a limited solubility may be employed where sustained release is desired. These compositions, in which the therapeutic drug is not totally solubilized in its dosage form provide a prolonged therapeutic activity.
  • a long chain carboxylic acid salt of the desired drug is often preferred.
  • the acid portion of the salt preferably contains from about 10 to about 30 carbon atoms.
  • the dosage forms of the present invention additionally comprise a pharmaceutically acceptable nasal carrier. Any of the benzodiazepines can be conveniently administered in such a carrier. These compositions comprise a systemic, therapeutically effective amount of the desired drug together with a pharmaceutically acceptable nasal carrier therefore.
  • Nasal carriers suitable in accordance with the present invention will be apparent to those skilled in the art of nasal pharmaceutical formulations.
  • exemplary nasal carriers include saline solutions; alcohols such as ethanol; glycols such as propylene glycol; glycol ethers such as polyethylene glycol and combinations of the foregoing with water and/or one another.
  • alcohols such as ethanol
  • glycols such as propylene glycol
  • glycol ethers such as polyethylene glycol and combinations of the foregoing with water and/or one another.
  • a therapeutic agent may, for example, be formulated into a nasal solution (for use as drops or as a spray), a nasal suspension, a nasal ointment, a nasal gel or any other nasal form.
  • Preferred nasal dosage forms are solutions, suspensions and gels. These normally contain a major amount of water (preferably purified water) in addition to the active hypnotic ingredient. Minor amounts of other ingredients such as tonicity agents (e.g.
  • NaCl NaCl
  • pH adjusters e.g., a base such as NaOH
  • emulsifiers or dispersing agents e.g., a base such as NaOH
  • buffering agents e.g., a preservatives
  • wetting agents and jelling agents e.g., methylcellulose
  • Particularly preferred compositions contain various of the foregoing other ingredients so as to be isotonic and/or buffered to the same pH as blood serum.
  • compositions may be administered to any of the subjects recognized as being susceptible to benzodiazepine hypnotics. While therefore generally useful in treatment of a broad spectrum of mammals, the present invention is most desirably employed on human subjects.
  • hypnotic drug is most clearly revealed by its concentration in the blood of the subject being treated.
  • hypnotic activity is dependent upon the bioavailability of therapeutic agent evidenced by that concentration. It is therefore particularly significant that the present nasal administration of benzodiazepines is characterized by a significantly faster onset and more pronounced blood concentration of hypnotic than conventional forms of administration. This insures an elevated and more constant hypnotic effect.
  • a systemic, therapeutically effective amount of a particular benzodiazepine hypnotic will vary with the particular drug as well as the type, age, size, weight and general physical condition of the subject. The amount will also vary dependent upon the particular therapeutic effect desired. Typically the dosage level will be more similar to the expected dosage level for intravenous administration than to the dosage levels currently employed for other methods of administration, for example, oral or rectal.
  • the present therapeutic compositions will normally be prepared in dosage unit forms to contain a systemic, therapeutically effective amount of the selected hypnotic drug.
  • the drug unit is normally less than 0.2 ml, optimally from 0.05 to 0.1 ml in volume.
  • nasal dosage units are prepared having a lesser amount of drug, preferably from one-half to one-tenth of the amount of therapeutic agent employed for conventional routes of administration. This is made possible through the improved blood concentration levels for benzodiazepines which have been observed to result from nasal administration. These are the most preferred types of compositions.
  • compositions are especially useful for improving sleep. They may be utilized to more rapidly induce and/or to prolong sleep. This use is not, however, exclusive.
  • present invention may likewise be employed to enhance other known therapeutic utilities of benzodiazepines.
  • triazolam solution was sprayed into both nostrils of the dogs.
  • the dose administered was determined by weighting the bottle containing the triazolam solution before and after spraying.
  • the dose given to each dog was 0.9343, 1.040, 1.422 and 1.532 mg respectively.
  • Blood sampling times were the same as in the oral study. The plasma samples were frozen until GC assay for triazolam.
  • GC Assay To extract triazolam, 0.5 ml of plasma, 50 ⁇ l of internal standard (55 ng/ml clonazepam in methanol) and 3 ml of hexane/methylene chloride (4:3) were vortexed together for 15 seconds and centrifuged for 4 minutes. The bottom aqueous layer was frozen by dry ice/acetone and the upper organic layer was transferred to another tube containing 1 ml of distilled water. The mixture was vortexed for 15 seconds and centrifuged for 4 minutes. Two ml of the upper organic layer was then pipetted into another tube and evaporated to dryness in an vortex-evaporator. Fifty ml of toluene was used for reconstitution.
  • the amount of triazolam in 3 ml of extract plasma was assayed by an HP model 5830A GC-EC.
  • the glass column used was a 6' ⁇ 1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb injcctor port and detector were 275°, 310° and 350° C., respectively.
  • the flow rate for argon/methane (95:5) gas 42 ml/min.
  • the average dose-corrected plasma concentration of triazolam for the dogs after oral and nasal administration of triazolam are shown shown in FIG. 1.
  • Plasma triazolam levels after nasal administration were consistently higher than those for oral administration
  • the oral plasma concentration-time curve shows more variability than with nasal administration. This is attributable to variability in gastric emptying of the tablets.
  • Table 1 shows the various relevant pharmacokinetic parameters obtained from this study.
  • Midazolam solution was sprayed, using a meter dose inhaler into both nostrils of the dogs.
  • the dose given to each dog was 7.85, 7.89, 7.22, 5.61 mg free base.
  • Blood sampling times were the same as in the oral study. The plasma samples were frozen until GC assay for midazolam.
  • GC Assay--for extraction 0.5 ml of plasma, 100 ⁇ l of internal standard (100 ng/ml flurazepam in methanol) and 0.5 ml of 2N sodium hydroxide were vortexed for 5 seconds. Five ml of hexane was then added and the mixture was vortexed for one min. and centrifuges for 4 minutes. Four ml of the upper organic layer was then pipetted into another tube and evaporated to dryness in an vortex-evaporator. Fifty ⁇ l of hexane/isoamyl alcohol (80:20) was used for reconstitution.
  • Midazolam in plasma was assayed by a Hewlett Packard model 5830A GC-EC.
  • the glass column used was a 6' ⁇ 1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb W-HP 80/100 packing (Anspec).
  • the temperatures for column, injector port and detector were 250°, 310° and 310° C., respectively.
  • the flow rate for argon/methane (95:5) gas was 33 ml/min.
  • the average dose-corrected plasma concentrations of midazolam for the dogs after oral and nasal administration of midazolam is shown in FIG. 2. Plasma midazolam levels after nasal administration were consistently higher than after oral administration.
  • Table 2 shows various relevant pharmacokinetic parameters obtained from this study.
  • the AUCs listed under nasal and oral administration were normalized with the dose administered. There was a mean of 2.5-fold increase in AUC after nasal administration. The Cmax after oral administration was 4 times lower than that of nasal route. The Tmax after nasal administration was 2-fold earlier than after oral administration. The mean half-life was about the same in both routes of administration. There was significant increase in bioavailability of midazolam after nasal versus oral administration.
  • Flurazepam solution was sprayed into both nostrils of the dogs.
  • the dose given to the dogs was 14.5, 12.4, 12.1 and 12.5 mg as flurazepam HCl.
  • Blood sampling times were same as in the oral study. The plasma samples were frozen until GC assay for flurazepam.
  • GC Assay For extraction, 0.5 ml of plasma, 50 ⁇ l of internal standard (100 ng/ml diazepam in methanol) and 0.5 ml of 2N sodium hydroxide were vortexed for 5 seconds. Five ml of hexane was then added and the mixture was vortexed together for one min. and centrifuged for 4 minutes. Four ml of the upper organic layer was then pipetted. Fifty ⁇ l of hexane/isoamyl alcohol was used for reconstitution.
  • Flurazepam in plasma was assayed by a Hewlett Packard model 5830A GC-EC.
  • the glass column used was a 6' ⁇ 1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb W-HP 80/100 packing (Anspec).
  • the temperatures for column, injector port and detector were 250°, 310° and 310° C., respectively.
  • the flow rate for argon/methane (95:5) gas was 33 ml/min.
  • the average dose-corrected plasma concentrations of flurazepam for each dog after oral and nasal administration of flurazepam are shown in FIG. 3. Plasma flurazepam levels after nasal administration were consistently higher than after oral administration.
  • Table 3 shows relevant pharmacokinetic parameters obtained from this study.
  • the AUC for oral administration was estimated up to the last data point because flurazepam was still in its distribution phase As a result, half-life of the compound was not calculated.
  • the AUCs listed under nasal and oral administration were normalized with the dose administered. There was a mean of 51-fold increase in AUC after nasal administration.
  • the Cmax after oral administration was 15 times lower than that of nasal route.
  • the Tmax after nasal administration was half that of oral route.
  • a variety of hypnotics including chloral hydrate, sodium pentobarbital and flurazepam were administered to Wistar rats to compare the efficacy of oral and nasal administration. Because the rats proved resistant to flurazepam by oral technique, no comparison of that compound was possible.
  • the animals were then placed in a constant temperature environment of 32° C.
  • the duration of sleeping time (measured by the loss and reappearance of the righting reflex) was recorded for each animal. The results within each group were then averaged.
  • Nasal Administration Studies The methodology of the oral studies was repeated with substitution of nasal administration of aqueous solutions through a fine catheter inserted into the nostril.
  • the therapeutic drug was dosed at a constant volume of 50 ⁇ l which would deliver an amount of the hypnotic which would be orally effective.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nasal administration of benzodiazepines is described as providing improved therapeutic effects as compared to conventional delivery techniques. The compositions comprise a benzodiazepine hypnotic in a pharmaceutically acceptable nasal carrier.

Description

.Iadd.This application is a continuation of application Ser. No. 07/937,045 filed Aug. 20, 1992, now abandoned, which is a reissue of U.S. Pat. No. 4,950,664..Iaddend.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to a novel form of certain hypnotic drugs and to their administration to mammals. They may be employed for any of the conventional purposes for which hypnotics are known, but especially for improving sleep.
Hypnotic drugs are a class of therapeutic agents which are commonly employed to induce and/or to prolong sleep. They may also be utilized to alleviate sleep disorders. Terms such as sedative, anti-anxiety agent, minor tranquilizer and anxiolytic are sometimes used somewhat interchangeably for such drugs because, in appropriate dosages, these hypnotics can produce similar effects.
There are a wide variety of hypnotic drugs. This term includes both barbiturates and non-barbiturates. Typical barbiturate hypnotics are aprobarbital and pentobarbital. Non-barbiturates recognized for their hypnotic activity include benzodiazepines; antihistamines having pronounced side effects such as diphenhydramine; serotonin initiators such as L-tryptophane; and various other drugs including ethinamate, chloral hydrate, ethchlorvynol, methyprylon and glutethimide. Their hypnotic effect is commonly attributed to a neurological mechanism involving depression of the central nervous system. That effect is also frequently accompanied by a mild reduction in such physiological functions as blood pressure and respiration.
PRIOR ART
Numerous hypnotic drugs are already known. Many, for example, are listed in the Physicians Desk Reference (PDR) published by Medical Economics Company, Inc. They are widely used therapeutically to improve sleep. Administration is generally performed either parenterally or, more usually, orally by means of pills, tablets and capsules. Their various uses are likewise well known.
Unfortunately, these drugs commonly exhibit a number of drawbacks when conventionally administered. Some have undesirable side effects. Many are inefficiently and variably absorbed from their current dosage forms. Further, the onset of their pharmacological activity is often delayed and/or the duration of that activity limited pursuant to ordinary oral, subcutaneous and/or intra-muscular administration.
Unlike the broad applicability of conventional routes of administration, the nasal delivery of therapeutic agents is a relatively recently discovered technique. It is also recognized only for specific agents. Representative disclosures of nasal administration of drugs include: U.S. Pat. No. 4,454,140 of Goldberg et al; U.S. Pat. No's. 4,428,883; 4,284,648; and 4,394,390 of Hussain and U.S. Pat. No. 4,624,965 of Wenig.
While nasal administration has become an accepted route of administration, the foregoing disclosures limit that mode of delivery to the specific drugs described. Moreover, it has been observed that many therapeutic agents cannot be usefully administered by this unusual route. Consequently, nasal administration remains a technique for which applicability is far from universal and the results unpredictable.
SUMMARY OF INVENTION
It has been discovered that certain known hypnotic drugs can normally be effectively administered to mammals, and especially to humans, in novel compositions. More specifically, these compositions are ones which contain a benzodiazepine hypnotic adapted for nasal administration and comprise a solution, suspension, ointment, gel or other useful nasal form. These nasal compositions may be employed for any of the known therapeutic purposes for which such hypnotics are known.
The utilization of a nasal form of these hypnotic drugs greatly facilitates administration. As compared with parenteral administration, for example, a simple aerosol container or a dropper will suffice for delivery. From a therapeutic standpoint, nasal administration often provides a hypnotic effect of improved duration. It may also be more efficiently and precisely controlled than through conventional means and permits a more rapid onset of activity. These and additional advantages of the present invention will become evident from the description and examples which follow.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention and particularly the Examples and Tables, will be more clearly understood when considered with the accompanying drawings in which:
FIG. 1 is a graphic depiction of the comparative results of Example 1;
FIG. 2 is a graphic depiction of the comparative results of Example 2; and
FIG. 3 is a graphic depiction of the comparative results of Example 3.
DETAILED DESCRIPTION OF THE INVENTION
Any benzodiazepine drug capable of exhibiting a hypnotic activity may be employed in accordance with the present invention. These particularly include diazepam, triazolam, midazolam, temazepam and flurazepam; although other, less common benzodiazepines may also be utilized.
Any pharmaceutically acceptable form of these benzodiazepine drugs may be utilized in accordance with the present invention. Generally the selected therapeutic agent is provided in the chemical form which has previously been found most efficacious for oral or parenteral delivery. Most commonly, this comprises either the free base or a pharmaceutically acceptable salt of the hypnotic agent.
A peculiar facet of the present invention lies in the discovery of the uniqueness of this class of hypnotics. Despite the recognized equivalence of benzodiazepines with other subclasses of hypnotics, they do not provide the many advantages enjoyed through the nasal administration of benzodiazepines. In fact, it has been discovered that many of these non-benzodiazepine hypnotics fail to exhibit that therapeutic activity when they are administered nasally, instead of by conventional method.
In the formulation of the present hypnotic compositions, a relatively water soluble form of the benzodiazepine is usually employed. Use of a fully dissolved form of the benzodiazepine maximizes its immediate effect. Compositions containing the therapeutic drug in a form having a limited solubility may be employed where sustained release is desired. These compositions, in which the therapeutic drug is not totally solubilized in its dosage form provide a prolonged therapeutic activity. For this purpose, a long chain carboxylic acid salt of the desired drug is often preferred. The acid portion of the salt preferably contains from about 10 to about 30 carbon atoms. Such salts, including stearates, palmitates and the like, are readily synthesized by known techniques.
The dosage forms of the present invention additionally comprise a pharmaceutically acceptable nasal carrier. Any of the benzodiazepines can be conveniently administered in such a carrier. These compositions comprise a systemic, therapeutically effective amount of the desired drug together with a pharmaceutically acceptable nasal carrier therefore.
Nasal carriers suitable in accordance with the present invention will be apparent to those skilled in the art of nasal pharmaceutical formulations. Exemplary nasal carriers include saline solutions; alcohols such as ethanol; glycols such as propylene glycol; glycol ethers such as polyethylene glycol and combinations of the foregoing with water and/or one another. For still other examples, reference is made to the text entitled "REMINGTON'S PHARMACEUTICAL SCIENCES", 14th edition, 1970.
The choice of a suitable carrier in accordance with the present invention will depend on the exact nature of the particular nasal dosage form required. A therapeutic agent may, for example, be formulated into a nasal solution (for use as drops or as a spray), a nasal suspension, a nasal ointment, a nasal gel or any other nasal form. Preferred nasal dosage forms are solutions, suspensions and gels. These normally contain a major amount of water (preferably purified water) in addition to the active hypnotic ingredient. Minor amounts of other ingredients such as tonicity agents (e.g. NaCl) pH adjusters (e.g., a base such as NaOH), emulsifiers or dispersing agents, buffering agents, preservatives, wetting agents and jelling agents (e.g., methylcellulose) may also be present. Particularly preferred compositions contain various of the foregoing other ingredients so as to be isotonic and/or buffered to the same pH as blood serum.
The present compositions may be administered to any of the subjects recognized as being susceptible to benzodiazepine hypnotics. While therefore generally useful in treatment of a broad spectrum of mammals, the present invention is most desirably employed on human subjects.
The efficacy of a hypnotic drug is most clearly revealed by its concentration in the blood of the subject being treated. In general, hypnotic activity is dependent upon the bioavailability of therapeutic agent evidenced by that concentration. It is therefore particularly significant that the present nasal administration of benzodiazepines is characterized by a significantly faster onset and more pronounced blood concentration of hypnotic than conventional forms of administration. This insures an elevated and more constant hypnotic effect.
Those skilled in the art will be aware that a systemic, therapeutically effective amount of a particular benzodiazepine hypnotic will vary with the particular drug as well as the type, age, size, weight and general physical condition of the subject. The amount will also vary dependent upon the particular therapeutic effect desired. Typically the dosage level will be more similar to the expected dosage level for intravenous administration than to the dosage levels currently employed for other methods of administration, for example, oral or rectal.
As a practical matter, the present therapeutic compositions will normally be prepared in dosage unit forms to contain a systemic, therapeutically effective amount of the selected hypnotic drug. This can be similar to conventional dosage amounts of the drug. The drug unit is normally less than 0.2 ml, optimally from 0.05 to 0.1 ml in volume. Desirably, nasal dosage units are prepared having a lesser amount of drug, preferably from one-half to one-tenth of the amount of therapeutic agent employed for conventional routes of administration. This is made possible through the improved blood concentration levels for benzodiazepines which have been observed to result from nasal administration. These are the most preferred types of compositions.
The present compositions are especially useful for improving sleep. They may be utilized to more rapidly induce and/or to prolong sleep. This use is not, however, exclusive. The present invention may likewise be employed to enhance other known therapeutic utilities of benzodiazepines.
The following examples are given by way of illustration only and are not to be considered limitations of this invention. Many apparent variations are possible without departing from the spirit or scope thereof.
EXAMPLE 1
In two comparative studies separated in time by over one week; four healthy male, 2-3 year old beagle dogs received oral and nasal doses of triazolam. They were fasted overnight before each study and food was withheld until the end of the experiment. They were restrained in a dog sling during the studies while blood (3 ml) was withdrawn from each dog through a cannula inserted into the cephalic vein.
Oral Administration Studies: Two 0.5 mg triazolam tablets were given to each dog with 50 ml of water. Blood samples were taken from the cephalic vein at 0 min before administration and 15, 30, 45, 60, 120, 180, 240, 300, 360 and 420 min after administration. The plasma samples were stored frozen until gas chromotographic assay for triazolam.
Nasal Administration Studies: Thirty milligrams of triazolam powder was dissolved in 5 ml of PEG 400 warmed at 55°-60° C. After the solution was cooled to room temperature, an equal volume of 1% methocel J5MS (Dow Chemical Company, Midland, Mich.) solution was mixed with the triazolam solution. Air bubbles generated during mixing were removed by centrifugation. The final concentration of triazolam in the solvent mixture was assayed by an HPLC method. An Altex C18, 4.6×150 mm column was used. The mobile phase contained 60% of 0.05 M KH2 PO4 (pH=6.0, T. J. Baker) and 40% acetonitrile (Fisher Scientific). Flow rate of mobile phase was 1 ml/min. The wavelength used was 221 nm. The assayed concentrations of triazolam solution range from 2.632 to 2.508 mg/ml.
Using a metered dose inhaler, triazolam solution was sprayed into both nostrils of the dogs. The dose administered was determined by weighting the bottle containing the triazolam solution before and after spraying. The dose given to each dog was 0.9343, 1.040, 1.422 and 1.532 mg respectively. Blood sampling times were the same as in the oral study. The plasma samples were frozen until GC assay for triazolam.
GC Assay: To extract triazolam, 0.5 ml of plasma, 50 μl of internal standard (55 ng/ml clonazepam in methanol) and 3 ml of hexane/methylene chloride (4:3) were vortexed together for 15 seconds and centrifuged for 4 minutes. The bottom aqueous layer was frozen by dry ice/acetone and the upper organic layer was transferred to another tube containing 1 ml of distilled water. The mixture was vortexed for 15 seconds and centrifuged for 4 minutes. Two ml of the upper organic layer was then pipetted into another tube and evaporated to dryness in an vortex-evaporator. Fifty ml of toluene was used for reconstitution.
The amount of triazolam in 3 ml of extract plasma was assayed by an HP model 5830A GC-EC. The glass column used was a 6'×1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb injcctor port and detector were 275°, 310° and 350° C., respectively. The flow rate for argon/methane (95:5) gas 42 ml/min.
Results
The average dose-corrected plasma concentration of triazolam for the dogs after oral and nasal administration of triazolam are shown shown in FIG. 1. Plasma triazolam levels after nasal administration were consistently higher than those for oral administration The oral plasma concentration-time curve shows more variability than with nasal administration. This is attributable to variability in gastric emptying of the tablets. Table 1 shows the various relevant pharmacokinetic parameters obtained from this study.
There was significant nasal absorption of triazolam. The mean AUC after nasal administration was 2.4-fold larger than that of oral route. Mean plasma triazolam concentration peaked at about 18.8 min. after nasal administration while that of oral route was about 48.8 min. The mean half-life was about the same in both routes of administration. The mean, peak plasma concentration was 27.6 ng/ml for nasal route and 7.0 ng/ml for oral administration. Thus nasal administration provided triazolam both sooner and in a greater amount than oral administration.
                                  TABLE 1                                 
__________________________________________________________________________
RELEVANT PHARMACOKINETIC PARAMETERS OF TRIAZOLAM                          
AFTER ORAL AND NASAL DELIVERY                                             
       1 AUC                                                              
           2 AUC                                                          
               3 AUC 4 CMAX                                               
                          5 CMAX                                          
                               6 TMAX                                     
                                    7 TMAX                                
                                         8 T1/2                           
                                             9 T1/2                       
0 NAME PO  NASAL                                                          
               NASAL/PO                                                   
                     PO   NASAL                                           
                               PO   NASAL                                 
                                         PO  NASAL                        
__________________________________________________________________________
1 DUNCAN                                                                  
       976.8                                                              
           2148.6                                                         
               2.20  7.60 27.20                                           
                               45.0 15.0 103.7                            
                                             62.7                         
2 GURNEY                                                                  
        911.4                                                             
           2335.2                                                         
               2.60  6.10 31.20                                           
                               60.0 15.0 58.8                             
                                             57.3                         
3 BUCKO                                                                   
        569.8                                                             
           1598.8                                                         
               2.80  5.50 25.20                                           
                               60.0 15.0 58.1                             
                                             65.3                         
4 EDRIK                                                                   
        670.4                                                             
           1415.2                                                         
               2.10  8.70 26.60                                           
                               30.0 30.0 49.4                             
                                             43.7                         
6 MEAN  782.1                                                             
           1874.5                                                         
               2.40  7.00 27.60                                           
                               48.8 18.8 67.5                             
                                             57.3                         
7 (SEM)                                                                   
        96.7                                                              
           218.8                                                          
               0.16  0.72 1.27 7.2  3.8  12.3                             
                                             4.8                          
__________________________________________________________________________
EXAMPLE 2
The efficacy of oral versus nasal administration of midazolam was examined using the methodology of Example 1, but modified to allow at least three weeks between studies.
Oral Administration Studies: Five mg equivalent of midazolam free base solution was given to each of four dogs with 50 ml of water. Blood samples were taken from the cephalic vein at 0 min before administration and 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after administration. The plasma samples were stored frozen until GC assay for midazolam.
Nasal Administration Studies: 55.6 milligrams of midazolam HCl powder was dissolved in 4 ml of distilled water. One ml of 7.5% methocel J5MS (Dow Chemical Company, Midland, Mich.) solution was mixed with the midazolam solution. Air bubbles generated during mixing were removed by centrifugation. The pH of the solution was 3.62.
Midazolam solution was sprayed, using a meter dose inhaler into both nostrils of the dogs. The dose given to each dog was 7.85, 7.89, 7.22, 5.61 mg free base. Blood sampling times were the same as in the oral study. The plasma samples were frozen until GC assay for midazolam.
GC Assay--for extraction, 0.5 ml of plasma, 100 μl of internal standard (100 ng/ml flurazepam in methanol) and 0.5 ml of 2N sodium hydroxide were vortexed for 5 seconds. Five ml of hexane was then added and the mixture was vortexed for one min. and centrifuges for 4 minutes. Four ml of the upper organic layer was then pipetted into another tube and evaporated to dryness in an vortex-evaporator. Fifty μl of hexane/isoamyl alcohol (80:20) was used for reconstitution.
Midazolam in plasma was assayed by a Hewlett Packard model 5830A GC-EC. The glass column used was a 6'×1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb W-HP 80/100 packing (Anspec). The temperatures for column, injector port and detector were 250°, 310° and 310° C., respectively. The flow rate for argon/methane (95:5) gas was 33 ml/min.
Results and Discussion
The average dose-corrected plasma concentrations of midazolam for the dogs after oral and nasal administration of midazolam is shown in FIG. 2. Plasma midazolam levels after nasal administration were consistently higher than after oral administration.
Table 2 shows various relevant pharmacokinetic parameters obtained from this study. The AUCs listed under nasal and oral administration were normalized with the dose administered. There was a mean of 2.5-fold increase in AUC after nasal administration. The Cmax after oral administration was 4 times lower than that of nasal route. The Tmax after nasal administration was 2-fold earlier than after oral administration. The mean half-life was about the same in both routes of administration. There was significant increase in bioavailability of midazolam after nasal versus oral administration.
                                  TABLE 2                                 
__________________________________________________________________________
RELEVANT PHARMACOKINETIC PARAMETERS OF MIDAZOLAM                          
AFTER ORAL AND NASAL DELIVERY                                             
       1 AUC*                                                             
           2 AUC*                                                         
               3 AUC 4 CMAX*                                              
                          5 CMAX#                                         
                               6 TMAX@                                    
                                     7 TMAX@                              
                                           8 T1/2@                        
                                                9 T1/2@                   
0 NAME PO  NASAL                                                          
               NASAL/PO                                                   
                     PO   NASAL                                           
                               PO    NASAL PO   NASAL                     
__________________________________________________________________________
1 DUNCAN                                                                  
       235.6                                                              
           842.9                                                          
               3.58  22.2 159.0                                           
                               15.0  15    43.5 36.1                      
2 GURNEY                                                                  
       242.0                                                              
           520.8                                                          
               2.15  15.0 111.2                                           
                               45.0  15    50.6 26.8                      
3 BUCKO                                                                   
        157.8                                                             
           338.5                                                          
               2.15  17.8 47.1 30.0  15    19.4 36.5                      
4 EDRIK                                                                   
        333.2                                                             
           650.8                                                          
               1.95  42.8 87.9 30.0  15    19.3 33.8                      
6 MEAN   242.1                                                            
           588.3                                                          
               2.46  24.5 101.0                                           
                               30.0  15    33.2 33.3                      
7 (SEM)                                                                   
        35.9                                                              
           106.4                                                          
               0.38  3.2  11.7 3.1   0     4.1  1.1                       
__________________________________________________________________________
 9 *ngmin/ml-mg                                                           
 10 #ng/ml                                                                
 11 @min
EXAMPLE 3
The efficacy of oral versus nasal administration was examined using the methodology of Example 2.
Oral Administration Studies: Fifteen mg of flurazepam HCl solution was given to each dog with 50 ml of water. Blood samples were taken from the cephalic vein at 0 min before administration and at 15, 30, 45, 60, 120, 180, 240, 300, 360 min after administration. The plasma samples were stored frozen until GC assay for flurazepam.
Nasal Administration Studies: One hundred and twenty milligrams of flurazepam HCl powder was dissolved in 4 ml of distilled water. One ml of 7.5% methocel J5MS (Dow Chemical Company, Midland, Mich.) solution was mixed with the flurazepam solution. Air bubbles generated during mixing were eliminated by centrifugation. The pH of the solution was 1.82.
Flurazepam solution was sprayed into both nostrils of the dogs. The dose given to the dogs was 14.5, 12.4, 12.1 and 12.5 mg as flurazepam HCl. Blood sampling times were same as in the oral study. The plasma samples were frozen until GC assay for flurazepam.
GC Assay: For extraction, 0.5 ml of plasma, 50 μl of internal standard (100 ng/ml diazepam in methanol) and 0.5 ml of 2N sodium hydroxide were vortexed for 5 seconds. Five ml of hexane was then added and the mixture was vortexed together for one min. and centrifuged for 4 minutes. Four ml of the upper organic layer was then pipetted. Fifty μl of hexane/isoamyl alcohol was used for reconstitution.
Flurazepam in plasma was assayed by a Hewlett Packard model 5830A GC-EC. The glass column used was a 6'×1/4" 2 mm on column w/o liner 6" coil (Anspec) with 3% OV-17 chromosorb W-HP 80/100 packing (Anspec). The temperatures for column, injector port and detector were 250°, 310° and 310° C., respectively. The flow rate for argon/methane (95:5) gas was 33 ml/min.
Results and Discussion
The average dose-corrected plasma concentrations of flurazepam for each dog after oral and nasal administration of flurazepam are shown in FIG. 3. Plasma flurazepam levels after nasal administration were consistently higher than after oral administration.
Table 3 shows relevant pharmacokinetic parameters obtained from this study. The AUC for oral administration was estimated up to the last data point because flurazepam was still in its distribution phase As a result, half-life of the compound was not calculated. The AUCs listed under nasal and oral administration were normalized with the dose administered. There was a mean of 51-fold increase in AUC after nasal administration. The Cmax after oral administration was 15 times lower than that of nasal route. The Tmax after nasal administration was half that of oral route.
                                  TABLE 3                                 
__________________________________________________________________________
RELEVANT PHARMACOKINETIC PARAMETERS OF FLURAZEPAM                         
AFTER ORAL AND NASAL DELIVERY                                             
       1 AUC*                                                             
           2 AUC*                                                         
               3 AUC 4 CMAX*                                              
                          5 CMAX#                                         
                               6 TMAX@                                    
                                     7 TMAX@                              
                                           8 T1/2@                        
                                                9 T1/2@                   
0 NAME PO  NASAL                                                          
               NASAL/PO                                                   
                     PO   NASAL                                           
                               PO    NASAL PO   NASAL                     
__________________________________________________________________________
1 DUNCAN                                                                  
       8.60                                                               
           922.3                                                          
               107.2 3.04 161.5                                           
                               15.0  15    *****                          
                                                214.7                     
2 GURNEY                                                                  
       19.30                                                              
           384.9                                                          
               19.9  8.85 41.1 15.0  15    *****                          
                                                190.8                     
3 BUCKO                                                                   
        4.81                                                              
           287.4                                                          
               59.9  2.06 31.5 45.0  15    *****                          
                                                163.3                     
4 EDRIK                                                                   
        20.00                                                             
           314.9                                                          
               15.7  5.91 59.0 30.0  15    *****                          
                                                102.6                     
6 MEAN   13.20                                                            
           477.4                                                          
               50.7  4.97 73.3 26.3  15    *****                          
                                                167.9                     
7 (SEM)                                                                   
        3.80                                                              
           149.7                                                          
               21.3  1.53 29.9 7.2   0     *****                          
                                                24.2                      
__________________________________________________________________________
 9 *ngmin/ml-mg                                                           
 10 #ng/ml                                                                
 11 @min
EXAMPLE 4
A variety of hypnotics including chloral hydrate, sodium pentobarbital and flurazepam were administered to Wistar rats to compare the efficacy of oral and nasal administration. Because the rats proved resistant to flurazepam by oral technique, no comparison of that compound was possible.
Oral Administration Studies: The subjects were fasted for approximately 18 hours; water was available ab libitum. Aqueous solutions of chloral hydrate obtained from Sigma Chemical Co., Ltd. and sodium pentobarbital were separately administered to groups of the subject rats using a constant dose volume of 10mg/kg. Different dosage levels were obtained by varying the aqueous concentrations of therapeutic drug to identify an effective amount of hypnotic.
The animals were then placed in a constant temperature environment of 32° C. The duration of sleeping time (measured by the loss and reappearance of the righting reflex) was recorded for each animal. The results within each group were then averaged.
Nasal Administration Studies: The methodology of the oral studies was repeated with substitution of nasal administration of aqueous solutions through a fine catheter inserted into the nostril. The therapeutic drug was dosed at a constant volume of 50 μl which would deliver an amount of the hypnotic which would be orally effective.
Results and Discussion
Wide variation of results between similarly treated subjects occurred for nasal administration. That variation was attributed to expulsion, as by sneezing, swallowing or inhalation. All of these physiological responses interfered with administration. Despite this interference, the data confirmed that these hypnotics, in contrast to benzodizaepines, are significantly less effective where administered nasally than by conventional technique.
The foregoing Examples are illustrative of the present invention. The scope of this invention is indicated by the appended claims, and all changes which come within the meaning and range of equivalency of these claims are intended to be embraced therein.

Claims (19)

What is claimed is:
1. A composition for the administration of a hypnotic drug comprising a systemically effective amount of a benzodiazepine in a pharmaceutically acceptable .Iadd.aqueous .Iaddend.nasal carrier.
2. The composition of claim 1, wherein the hypnotic drug comprises the free base or pharmaceutically acceptable salt of a benzodiazepine.
3. The composition of claim 1, wherein the benzodiazepine is totally solubilized in the carrier.
4. The composition of claim 2, wherein a portion of the benzodiazepine is dispersed in undissolved form in the carrier.
5. The composition of claim 2, wherein the benzodiazepine comprises triazolam.
6. The composition of claim 2, wherein the benzodiazepine comprises midazolam.
7. The composition of claim 2, wherein the benzodiazepine comprises temazepam.
8. The composition of claim 2, wherein the benzodiazepine .[.is.]. .Iadd.comprises .Iaddend.diazepam.
9. The composition of claim 2, wherein the benzodiazepine comprises flurazepam.
10. A method for inducing an improved pharmacological response in a mammal comprising the nasal administration of a composition comprising a systemically effective amount of a benzodiazepine in a pharmaceutically acceptable .Iadd.aqueous .Iaddend.nasal carrier.
11. The method of claim 10, wherein the benzodiazepine is essentially totally solubilized in the carrier to induce an improved onset of pharmacological response.
12. The method of claim 10, wherein the composition is nasally administered to a human subject in an amount effective for the improvement of sleep.
13. The composition of claim 2, wherein the pharmaceutically acceptable salt of a benzodiazepine is a carboxylic acid salt having from about 10 to about 30 carbon atoms.
14. The method of claim 10, wherein the pharmaceutically acceptable salt of a benzodiazepine is a carboxylic acid salt having from about 10 to about 30 carbon atoms.
15. The composition of claim 2, wherein the benzodiazepine is in a solution, suspension or gel .[.composed in major amount of.]. .Iadd.which includes .Iaddend.water.
16. The method of claim 10, wherein the benzodiazepine is in a solution, suspension or gel .[.composed in major amount of.]. .Iadd.which includes .Iaddend.water. .Iadd.17. The composition of claim 1, wherein the carrier is composed of water..Iaddend..Iadd.18. The composition of claim 17, having the physical form of a spray..Iaddend..Iadd.19. The composition of claim 18, wherein the benzodiazepine is selected from the group consisting of triazolam, midazolam, temazepam, diazepam and flurazepam..Iaddend..Iadd.20. The composition of claim 1, wherein the
carrier consists essentially of water..Iaddend..Iadd.21. The composition
of claim 17 filled in an aerosol container..Iaddend..Iadd.22. The composition of claim 1, wherein the benzodiazepine is in a solution, suspension or gel composed in major amount of water..Iaddend..Iadd.23. The composition of claim 22, having the physical form of a spray..Iaddend..Iadd.24. The composition of claim 22 filed in an aerosol
container..Iaddend..Iadd.25. A method for treating a mammal suffering from anxiety comprising administering nasally a systemically effective amount of midazolam in a pharmaceutically acceptable nasal carrier during a period of anxiety..Iaddend.
US08/213,498 1988-09-16 1994-03-16 Nasal administration of benzodiazepine hypnotics Expired - Lifetime USRE36744E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/213,498 USRE36744E (en) 1988-09-16 1994-03-16 Nasal administration of benzodiazepine hypnotics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/245,031 US4950664A (en) 1988-09-16 1988-09-16 Nasal administration of benzodiazepine hypnotics
US93704592A 1992-08-20 1992-08-20
US08/213,498 USRE36744E (en) 1988-09-16 1994-03-16 Nasal administration of benzodiazepine hypnotics

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US07/245,031 Reissue US4950664A (en) 1988-09-16 1988-09-16 Nasal administration of benzodiazepine hypnotics
US93704592A Continuation 1988-09-16 1992-08-20

Publications (1)

Publication Number Publication Date
USRE36744E true USRE36744E (en) 2000-06-20

Family

ID=26936967

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/213,498 Expired - Lifetime USRE36744E (en) 1988-09-16 1994-03-16 Nasal administration of benzodiazepine hypnotics

Country Status (1)

Country Link
US (1) USRE36744E (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089751A1 (en) * 2001-02-20 2002-11-14 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20030163099A1 (en) * 2000-08-15 2003-08-28 Wermeling Daniel P Programmable multi-dose intranasal drug delivery device
US6716415B2 (en) 2001-05-24 2004-04-06 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US6737043B2 (en) 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20040171609A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2005089768A1 (en) * 2004-03-17 2005-09-29 University Of Kentucky Research Foundation Intranasal benzodiazepine compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20080004305A1 (en) * 2000-05-10 2008-01-03 Wermeling Daniel P Intranasal Opioid Compositions
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20090227568A1 (en) * 2007-01-19 2009-09-10 Sveinbjorn Gizurarson Methods and compositions for the delivery of a therapeutic agent
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8387612B2 (en) 2003-05-21 2013-03-05 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8507468B2 (en) 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US12214119B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906265A (en) * 1957-09-03 1959-09-29 Maryland Devices Inc Nasal adaptor for valved dispenser
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
EP0005120A1 (en) * 1978-04-18 1979-10-31 Etablissements Françon et Cie (société anonyme) Device for rendering stanchions or posts of transport vehicles removable and securable
US4244945A (en) * 1977-07-22 1981-01-13 Burroughs Wellcome Co. Biologically active substance
JPS5649313A (en) * 1979-08-03 1981-05-02 Uni Kentatsukii Research Fuand Propranolol novel dosage
WO1982003009A1 (en) * 1981-03-06 1982-09-16 Kentucky Res Found Univ Nasal administration of beta-blockers and dosage forms therefor
US4381773A (en) * 1980-06-23 1983-05-03 Schering Corporation Method and nozzle for nasal vaccination of immature mammals
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS6147415A (en) * 1984-08-10 1986-03-07 山之内製薬株式会社 Nasal medicinal composition
WO1986002553A1 (en) * 1984-10-23 1986-05-09 Nastech Pharmaceutical Company, Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
JPS63503303A (en) * 1986-03-10 1988-12-02 ブルグハルト，クルト Pharmaceutical preparations and their manufacturing methods
US4789667A (en) * 1984-09-03 1988-12-06 Teijin Limited External pharmaceutical composition and methods of use
US4814161A (en) * 1985-01-16 1989-03-21 Riker Laboratories, Inc. Drug-containing chlorofluorocarbon aerosol propellent formulations
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
EP0183527B1 (en) * 1984-11-26 1991-03-13 Yamanouchi Pharmaceutical Co. Ltd. Absorbable calcitonin medicament
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906265A (en) * 1957-09-03 1959-09-29 Maryland Devices Inc Nasal adaptor for valved dispenser
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4244945A (en) * 1977-07-22 1981-01-13 Burroughs Wellcome Co. Biologically active substance
EP0005120A1 (en) * 1978-04-18 1979-10-31 Etablissements Françon et Cie (société anonyme) Device for rendering stanchions or posts of transport vehicles removable and securable
JPS5649313A (en) * 1979-08-03 1981-05-02 Uni Kentatsukii Research Fuand Propranolol novel dosage
US4284648A (en) * 1979-08-03 1981-08-18 The University Of Kentucky Research Foundation Nasal administration of propranolol
US4381773A (en) * 1980-06-23 1983-05-03 Schering Corporation Method and nozzle for nasal vaccination of immature mammals
WO1982003009A1 (en) * 1981-03-06 1982-09-16 Kentucky Res Found Univ Nasal administration of beta-blockers and dosage forms therefor
JPS58500562A (en) * 1981-03-06 1983-04-14 ザ　ユニバ−シテイ−　オブ　ケンタツキ−　リサ−チ　フアウンデ−シヨン Novel administration methods for blocking agents and novel dosage forms containing the blocking agents
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS6147415A (en) * 1984-08-10 1986-03-07 山之内製薬株式会社 Nasal medicinal composition
US4885305A (en) * 1984-08-10 1989-12-05 Yamanouchi Pharmaceutical Co., Ltd. Nasal compositions
US4789667A (en) * 1984-09-03 1988-12-06 Teijin Limited External pharmaceutical composition and methods of use
WO1986002553A1 (en) * 1984-10-23 1986-05-09 Nastech Pharmaceutical Company, Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
JPS62500589A (en) * 1984-10-23 1987-03-12 ナステツク　フア−マス−テイカル　カンパニ−、インコ−ポレイテツド Novel dosage compositions for anti-nausea and anti-emetic drugs
EP0183527B1 (en) * 1984-11-26 1991-03-13 Yamanouchi Pharmaceutical Co. Ltd. Absorbable calcitonin medicament
US4814161A (en) * 1985-01-16 1989-03-21 Riker Laboratories, Inc. Drug-containing chlorofluorocarbon aerosol propellent formulations
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
JPS63503303A (en) * 1986-03-10 1988-12-02 ブルグハルト，クルト Pharmaceutical preparations and their manufacturing methods
US4863720A (en) * 1986-03-10 1989-09-05 Walter Burghart Pharmaceutical preparation and methods for its production
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Drug Delivery System" edited by Hitoshi Sezaki (Apr. 15, 1986), published by Nankodo, pp. 126-128.
"Revised Version of handbook of Pharmaceuticals" edited by Osaka-Pref. Hospital-Pharmaceutist Association (Sho. 61-9-10), published by Yakugyo-Jihosha, pp. 16-19, 40-41, 136-143.
Danish Pharmaceutical Catalogue 1987 (Laegemiddelkataloget 1987); pp. 277 278, 282, 527, 820, 853 854 and 910 (including translations of relevant parts). *
Danish Pharmaceutical Catalogue 1987 (Laegemiddelkataloget 1987); pp. 277-278, 282, 527, 820, 853-854 and 910 (including translations of relevant parts).
Drug Delivery System edited by Hitoshi Sezaki (Apr. 15, 1986), published by Nankodo, pp. 126 128. *
Martindale 1982, pp. 1526, 1543 1544 and 1728. *
Martindale 1982, pp. 1526, 1543-1544 and 1728.
Morimoto et al., "Nasal Absorption Of Nifedipine From Gel Preparations In Rats", Chem. Pharm. Bull, 35(7):3041 3044 (1987).
Morimoto et al., Nasal Absorption Of Nifedipine From Gel Preparations In Rats , Chem. Pharm. Bull , 35(7):3041 3044 (1987). *
Revised Version of handbook of Pharmaceuticals edited by Osaka Pref. Hospital Pharmaceutist Association (Sho. 61 9 10), published by Yakugyo Jihosha, pp. 16 19, 40 41, 136 143. *
The Merck Index (1983), p. 886:6056. *
The Merck Index, 10th Edition, (1983), pp. 1308 1309. *
The Merck Index, 10th Edition, (1983), pp. 1308-1309.
Wilton et al., "Intranasal Midazolam Premedication In Pre-School Children", Anesthesia and Analgesia, 67:S260 (1988), published in Feb. 1988.
Wilton et al., Intranasal Midazolam Premedication In Pre School Children , Anesthesia and Analgesia , 67:S260 (1988), published in Feb. 1988. *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070209660A1 (en) * 2000-05-10 2007-09-13 Wermeling Daniel P Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same
US20080004305A1 (en) * 2000-05-10 2008-01-03 Wermeling Daniel P Intranasal Opioid Compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20030206867A1 (en) * 2000-05-10 2003-11-06 Wermeling Daniel P. System and method for intranasal administration of lorazepam
US8198291B2 (en) 2000-05-10 2012-06-12 University Of Kentucky Research Foundation Intranasal opioid compositions
US20110118294A1 (en) * 2000-05-10 2011-05-19 Wermeling Daniel P Intranasal Opioid Compositions
US20110023870A1 (en) * 2000-05-10 2011-02-03 Wermeling Daniel P Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same
US20100331354A1 (en) * 2000-05-10 2010-12-30 Wermeling Daniel P Intranasal Opioid Compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060147386A1 (en) * 2000-05-10 2006-07-06 Wermeling Daniel P System and method for intranasal administration of lorazepam
US7559321B2 (en) 2000-08-15 2009-07-14 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US6948492B2 (en) 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20030163099A1 (en) * 2000-08-15 2003-08-28 Wermeling Daniel P Programmable multi-dose intranasal drug delivery device
US20060021614A1 (en) * 2000-08-15 2006-02-02 Wermeling Daniel P Programmable multi-dose intranasal drug delivery service
US20100113426A1 (en) * 2001-02-20 2010-05-06 Wermeling Daniel P Intranasal Benzodiazepine Compositions
US20070071687A1 (en) * 2001-02-20 2007-03-29 Wermeling Daniel P Intranasal benzodiazepine compositions
WO2002089751A1 (en) * 2001-02-20 2002-11-14 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US7449173B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7115250B2 (en) 2001-05-24 2006-10-03 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US6855310B2 (en) 2001-05-24 2005-02-15 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20040228807A1 (en) * 2001-05-24 2004-11-18 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US7018619B2 (en) 2001-05-24 2006-03-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20050089479A1 (en) * 2001-05-24 2005-04-28 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7060255B2 (en) 2001-05-24 2006-06-13 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7063831B2 (en) 2001-05-24 2006-06-20 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7070764B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US7070765B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7070762B2 (en) 2001-05-24 2006-07-04 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US6803031B2 (en) 2001-05-24 2004-10-12 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
US7078017B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7078019B2 (en) 2001-05-24 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7087216B2 (en) 2001-05-24 2006-08-08 Rabinowitz Joshua D Delivery of sedative-hypnotics through an inhalation route
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20060233718A1 (en) * 2001-05-24 2006-10-19 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20060251587A1 (en) * 2001-05-24 2006-11-09 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US6716415B2 (en) 2001-05-24 2004-04-06 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US20060286042A1 (en) * 2001-05-24 2006-12-21 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US20040191182A1 (en) * 2001-05-24 2004-09-30 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US20040185004A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of erectile dysfunction drugs through an inhalation route
US20040185003A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7445768B2 (en) 2001-05-24 2008-11-04 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7449175B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7988952B2 (en) 2001-05-24 2011-08-02 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7449174B2 (en) 2001-05-24 2008-11-11 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6737043B2 (en) 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20040127490A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20040126329A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US10350157B2 (en) 2001-05-24 2019-07-16 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7942147B2 (en) 2001-06-05 2011-05-17 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US8074644B2 (en) 2001-06-05 2011-12-13 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US11065400B2 (en) 2001-06-05 2021-07-20 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7537009B2 (en) 2001-06-05 2009-05-26 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US9687487B2 (en) 2001-06-05 2017-06-27 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7045119B2 (en) 2001-11-09 2006-05-16 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20040171609A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20040170571A1 (en) * 2001-11-09 2004-09-02 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7470421B2 (en) 2001-11-09 2008-12-30 Alexza Pharmaceuticals, Inc Delivery of diazepam through an inhalation route
US20060269486A1 (en) * 2001-11-09 2006-11-30 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US7087218B2 (en) 2001-11-09 2006-08-08 Alexza Pharmaceuticals, Inc. Delivery of diazepam through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7987846B2 (en) 2002-05-13 2011-08-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US8387612B2 (en) 2003-05-21 2013-03-05 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
WO2005089768A1 (en) * 2004-03-17 2005-09-29 University Of Kentucky Research Foundation Intranasal benzodiazepine compositions
US8333197B2 (en) 2004-06-03 2012-12-18 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US10052333B2 (en) 2007-01-19 2018-08-21 University Of Iceland Methods and systems for the delivery of a therapeutic agent
US8217033B2 (en) 2007-01-19 2012-07-10 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20090227568A1 (en) * 2007-01-19 2009-09-10 Sveinbjorn Gizurarson Methods and compositions for the delivery of a therapeutic agent
US9687495B2 (en) 2007-01-19 2017-06-27 Hananja Ehf Methods and systems for the delivery of a therapeutic agent
US9289432B2 (en) 2007-01-19 2016-03-22 HANANJA EHF and UNIVERSITY OF ICELAND Methods and compositions for the delivery of a therapeutic agent
US8809322B2 (en) 2007-01-19 2014-08-19 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US12138383B2 (en) 2007-03-09 2024-11-12 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8507468B2 (en) 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
US12214119B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device

Similar Documents

Publication Publication Date Title
US4950664A (en) Nasal administration of benzodiazepine hypnotics
USRE36744E (en) Nasal administration of benzodiazepine hypnotics
KR100345824B1 (en) Intranasal Formulations for Treating Sexual Disorders
AU714303B2 (en) Formulation for intranasal administration
AU2016253689B2 (en) Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US6509005B1 (en) Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US4749700A (en) Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
AU2002363443B2 (en) New uses for anti-malarial therapeutic agents
US20030130297A1 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
HUP0301518A2 (en) Dry powder composition for the treatment of respiratory diseases and process for its preparation
JP2012116841A (en) Aerosol preparation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation
CZ281931B6 (en) Sulfate of 3-£2-(dimethylamino)ethyl|-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof
AU2002363443A1 (en) New uses for anti-malarial therapeutic agents
US20090246256A1 (en) Compositions and Methods for Transmucosal Delivery of Lofexidine
US20050232871A1 (en) Use of compounds in a dry powder inhaler
US4729997A (en) Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
CA2483090A1 (en) Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions
EA009935B1 (en) New synergistic combination comprising roflumilast and formoterol
CY1490A (en) Improvements in or relating to nasal pharmaceutical compositions
AU2012261584B2 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: RIBOGENE, INC., CALIFORNIA

Free format text: REMOVAL OF SECURITY INTEREST;ASSIGNORS:HYLINE LABORATORIES, INC.;ASHKIN, MICHAEL;REEL/FRAME:012928/0584

Effective date: 20020508

AS Assignment

Owner name: QUESTCOR PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RIBOGENE, INC.;REEL/FRAME:013011/0227

Effective date: 20020619